Skip to main content

Table 2 Hemagglutination inhibition (HI) antibody response against the recombinant A/Vietnam/1194/2004 vaccine strain

From: The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study

 

Participants without priming (n = 71)

Participants primed with A/Indonesia/05/2005 (n = 34)

Participants primed with A/Vietnam/1194/2004 and A/Indonesia/05/2005 (n = 26)

Base line

   

GMTa

20 (14–29)

25 (17–39)

73 (40–133)

Seroprotective rateb (%)

49 (37–61)

59 (41–75)

73 (52–88)

Three weeks after 1 st immunization

   

GMT

23 (16–34)

32 (20–51)

163 (91–290)

Seroprotective rate (%)

55 (43–67)

65 (46–80)

85 (65–96)

Seroconversion ratec (%)

8 (3–17)

9 (2–24)

27 (12–48)

Three weeks after 2 nd immunization

   

GMT

29 (19–45)

41 (24–68)

176 (100–312)

Seroprotective rate (%)

63 (51–75)

68 (49–83)

88 (70–98)

Seroconversion rate (%)

21 (12–32)

21 (9–38)

35 (17–56)

  1. aGMT = geometric mean titer. A GMT of HI test result of a dilution of greater than 1:640 was recorded as a HI titer of 640.
  2. bSeroprotective rate is defined as the proportion of participants with a HI titer of 40 or greater.
  3. cSeroconversion rate is defined as the percentage of participants who have a HI titer of less than 10 before vaccination and a titer of more than 40 after vaccination or have a HI titer of more than 10 before vaccination and at least a four-fold increase in titer after vaccination.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us